Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in March 2018 on request of the sponsor.
On 23 February 2011, orphan designation (EU/3/10/834) was granted by the European Commission to Talecris Biotherapeutics GmbH, Germany, for human plasmin for the treatment of acute peripheral arterial occlusion.
In January 2012, Talecris Biotherapeutics GmbH changed name to Grifols Deutschland GmbH.
Treatment of acute peripheral arterial occlusion
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: